DE69633016D1 - Optisch reines (-) norcisaprid zur behandlung von krankheiten des verdauungstrakt - Google Patents

Optisch reines (-) norcisaprid zur behandlung von krankheiten des verdauungstrakt

Info

Publication number
DE69633016D1
DE69633016D1 DE69633016T DE69633016T DE69633016D1 DE 69633016 D1 DE69633016 D1 DE 69633016D1 DE 69633016 T DE69633016 T DE 69633016T DE 69633016 T DE69633016 T DE 69633016T DE 69633016 D1 DE69633016 D1 DE 69633016D1
Authority
DE
Germany
Prior art keywords
optically pure
norcisaprid
digestive tract
treating diseases
norcisapride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69633016T
Other languages
English (en)
Other versions
DE69633016T2 (de
Inventor
John R Mccullough
A K Gunnar Aberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunovion Pharmaceuticals Inc
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Application granted granted Critical
Publication of DE69633016D1 publication Critical patent/DE69633016D1/de
Publication of DE69633016T2 publication Critical patent/DE69633016T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69633016T 1995-06-07 1996-05-17 Optisch reines (-) norcisaprid zur behandlung von krankheiten des verdauungstrakt Expired - Fee Related DE69633016T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US485570 1995-06-07
US08/485,570 US5712293A (en) 1995-06-07 1995-06-07 Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride
PCT/US1996/007159 WO1996040133A1 (en) 1995-06-07 1996-05-17 Optically pure (-) norcisapride for treating digestive tract disorders

Publications (2)

Publication Number Publication Date
DE69633016D1 true DE69633016D1 (de) 2004-09-02
DE69633016T2 DE69633016T2 (de) 2004-12-23

Family

ID=23928664

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69633016T Expired - Fee Related DE69633016T2 (de) 1995-06-07 1996-05-17 Optisch reines (-) norcisaprid zur behandlung von krankheiten des verdauungstrakt
DE69636877T Expired - Fee Related DE69636877T2 (de) 1995-06-07 1996-05-17 Optisch reines (-) norcisaprid zur Behandlung von Krankheiten des Verdauungstraktes

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69636877T Expired - Fee Related DE69636877T2 (de) 1995-06-07 1996-05-17 Optisch reines (-) norcisaprid zur Behandlung von Krankheiten des Verdauungstraktes

Country Status (11)

Country Link
US (4) US5712293A (de)
EP (2) EP1462104B1 (de)
JP (1) JPH11510477A (de)
AT (2) ATE271870T1 (de)
AU (1) AU720407B2 (de)
CA (1) CA2224005A1 (de)
DE (2) DE69633016T2 (de)
DK (1) DK0831821T3 (de)
ES (2) ES2222480T3 (de)
PT (1) PT831821E (de)
WO (1) WO1996040133A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712293A (en) * 1995-06-07 1998-01-27 Sepracor, Inc. Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride
AU780107B2 (en) * 1996-07-19 2005-03-03 Sepracor, Inc. Methods for treating emesis and central nervous system disorders using optically pure () norcisapride
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
US6147093A (en) 1996-07-19 2000-11-14 Sepracor Inc. Methods for treating gastroesophageal reflux disease
US8128963B2 (en) * 1996-09-27 2012-03-06 The Trustees Of Columbia University In The City Of New York Methods for treating ischemic disorders using carbon monoxide
DE69714279T2 (de) * 1996-10-15 2003-03-06 Janssen Pharmaceutica Nv Verfahren zur Herstellung eines Zwischenprodukts in der Cisapridsynthese
DK1000029T3 (da) * 1997-07-11 2004-02-23 Janssen Pharmaceutica Nv Norcisaprid nyttig med hensyn til 5-HT3- og 5-HT4- medierede lidelser
TR200103757T2 (tr) * 1998-06-15 2002-06-21 Sepracor Inc. Apne, bulimi ve başka bozuklukların tedavi edilmesi için optik açıdan saf (-) norsisapridin kullanımı
EP1464333A3 (de) * 1998-06-15 2004-12-15 Sepracor Inc. Verwendung von optisch reines (-) Norcisapride in der Behandlung von Apnea, Bulimia und andere Krankheiten
US6353005B1 (en) 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
US6362202B1 (en) * 1999-03-02 2002-03-26 Sepracor Inc. Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
US7678390B2 (en) * 1999-04-01 2010-03-16 Yale University Carbon monoxide as a biomarker and therapeutic agent
US20040092511A1 (en) * 1999-12-10 2004-05-13 Billstein Stephan Anthony Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders
AU2002318377B2 (en) * 2001-06-21 2008-06-19 Beth Israel Deaconess Medical Center, Inc. Carbon monoxide improves outcomes in tissue and organ transplants and suppresses apoptosis
EP1472222A1 (de) * 2002-02-08 2004-11-03 Glaxo Group Limited Piperidylcarbonsäure amidderivate und deren verwendung zur behandlung von durch tachykinin vermittelten erkrankungen
EA200401070A1 (ru) * 2002-02-13 2005-02-24 Бет Изрейэл Диконисс Медикал Сентер, Инк. Способы лечения сосудистых заболеваний
JP2005522521A (ja) 2002-04-15 2005-07-28 ベス イスラエル デアコネス メディカル センター ヘムオキシゲナーゼ−１およびヘム分解産物の使用法
RS91004A (en) * 2002-04-15 2007-02-05 University Of Pittsburgh Of The Commonwealth System Of Higher Education, Methods of treating ileus
WO2003088981A1 (en) * 2002-04-15 2003-10-30 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methods of treating necrotizing enterocolitis
RS99304A (en) * 2002-05-17 2007-04-10 Yale University, Methods of treating hepatitis
UA87438C2 (ru) * 2002-06-05 2009-07-27 Йельский Университет Способы лечения или профилактики рака, способ проведения хирургической операции по удалению рака и применения монооксида углерода
WO2004000368A1 (en) * 2002-06-21 2003-12-31 University Of Pittsburgh Of The Commonwealth System Of Higher Education Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation
RS20050344A (en) * 2002-11-07 2007-11-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education, Treatment for hemorrhagic shock
PT1704146E (pt) 2004-01-07 2010-06-30 Aryx Therapeutics Inc Compostos estereoisoméricos e processos para o tratamento de distúrbios gastrointestinais e do sistema nervoso central
US8524736B2 (en) 2004-01-07 2013-09-03 Armetheon, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
US8138204B2 (en) * 2004-01-07 2012-03-20 Aryx Therapeutics, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
AU2006284601B2 (en) * 2005-08-31 2012-12-20 Renexxion, Llc Synthetic methods and intermediates for stereoisomeric compounds useful for the treatment of gastrointestinal and central nervous system disorders
WO2007149929A1 (en) * 2006-06-23 2007-12-27 Aryx Therapeutics, Inc. Piperidine derivatives for the treatment of gastrointestinal and cns disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3639002A (en) * 1970-04-06 1972-02-01 Gulf & Western Metals Forming Seat construction
US5137896A (en) * 1981-10-01 1992-08-11 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US4962115A (en) * 1981-10-01 1990-10-09 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US5057525A (en) * 1981-10-01 1991-10-15 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl) benzamide derivatives
CA1183847A (en) * 1981-10-01 1985-03-12 Georges Van Daele N-(3-hydroxy-4-piperidinyl)benzamide derivatives
CA2139636A1 (en) * 1992-07-07 1994-01-20 Nancy M. Gray Methods of using (+) cisapride for the treatment of gastro-esophageal reflux disease and other disorders
CA2139638A1 (en) * 1992-07-07 1994-01-20 Nancy M. Gray Methods of using (-) cisapride for the treatment of gastro-esophageal reflux disease and other disorders
JPH08512322A (ja) * 1993-07-06 1996-12-24 メルク エンド カンパニー インコーポレーテッド Ｈ▲下２▼拮抗剤−胃腸運動性の薬剤組合せ物
US5712293A (en) * 1995-06-07 1998-01-27 Sepracor, Inc. Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride

Also Published As

Publication number Publication date
EP1462104B1 (de) 2007-01-24
JPH11510477A (ja) 1999-09-14
ES2276194T3 (es) 2007-06-16
DE69633016T2 (de) 2004-12-23
WO1996040133A1 (en) 1996-12-19
ATE352304T1 (de) 2007-02-15
US6156770A (en) 2000-12-05
DE69636877D1 (de) 2007-03-15
EP0831821A1 (de) 1998-04-01
DE69636877T2 (de) 2007-05-31
ATE271870T1 (de) 2004-08-15
PT831821E (pt) 2004-11-30
AU720407B2 (en) 2000-06-01
EP1462104A1 (de) 2004-09-29
US5877189A (en) 1999-03-02
EP0831821B1 (de) 2004-07-28
US5712293A (en) 1998-01-27
DK0831821T3 (da) 2004-11-22
US6313144B1 (en) 2001-11-06
CA2224005A1 (en) 1996-12-19
AU5753396A (en) 1996-12-30
ES2222480T3 (es) 2005-02-01

Similar Documents

Publication Publication Date Title
DE69633016D1 (de) Optisch reines (-) norcisaprid zur behandlung von krankheiten des verdauungstrakt
DE69739792D1 (de) Verfahren zur Behandlung von Augenerkrankungen
NO973516D0 (no) Behandling av urininkontinens ved anvendelse av (S)-oksybutenin og (S)-desetyloksybutenin
DE19875011I2 (de) Verwendung von Sertindol zur Behandlung von Schiz ophrenie.
GEP20053720B (en) Triamide-Substituted Indoles, Benzofuranes and Benzothiophenes as Inhibitors of Microsomal Triglyceride Transfer Protein (MTP) and/or Apolipoprotein B (Apo B) Secretion
DE69824421D1 (de) Verfahren zur behandlung von zns-beteiligten lysosmalen speicherkrankheiten
DE69943107D1 (de) Behandlung von autoimmunerkrankungen
ATE251139T1 (de) (+)-norcisapride verwendbar bei 5-ht3 und 5-ht4 bedingten krankheiten
DE69725879D1 (de) VERWENDUNG VON p-AMINOPHENOLDERIVATEN ZUR HERSTELLUNG VON PHARMAZEUTISCHEN ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON NEURODEGENERATIVEN ERKRANKUNGEN
DE69819110D1 (de) Ein Arzneimittel zur Behandlung von Fettleibigkeit und Verbesserung des lipidmetabolismus
DE69328838D1 (de) Antipyretische und analgetische verfahren und zusammensetzungen, die optisch reines r-etodolac enthalten
ATE225177T1 (de) Verwendung von (+)mefloquine zur behandlung von malaria
ATE239470T1 (de) Melatonin-derivate zur verwendung in der behandlung von desynchronisierungs-erkankungen
DE69621786T2 (de) Aminotetralinderivat zur behandlung von herzkreislauferkrankung
DE69419954T2 (de) Arzneimittel zur Behandlung von Hauterkrankungen
NO20045089L (no) Substituerte aminoalkanfosfonsyrer for behandling av neuropatisk smerte, affektive og oppmerksomhetsforstyrrelser, schizofreni, tinnitus, myopi og andre okulaere lidelser
DE69736180D1 (de) Behandlung von manischen erkrankungen
ATE235237T1 (de) Sertralin zur behandlung von post-myocard-infarkt-patienten
DE69906728D1 (de) Verwendung von 4-piperidinmethanolderivaten zur behandlung von neuralentwicklungsstörungen
DE69421705D1 (de) Verwendung von Efaroxan und dessen Derivaten zur Herstellung eines Arzneimittels zur Behandlung neurogenerativer Erkrankungen
GR3034919T3 (en) Methods and compositions for treating infection using optically pure (r)-lomefloxacin.
DE69830811D1 (de) Verwendung von Oxazolidinonderivaten zur Behandlung von Psoriasis
ATE232098T1 (de) Verwendung von efaroxan zur herstellung eines arzneimittels zur behandlung von huntington krankheit

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee